Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma
Overview
Authors
Affiliations
Background: The present study aimed to clarify the clinicopathologic features of long-term disease-fee survival after resection of hepatocellular carcinoma (HCC).
Methods: This retrospective study identified 940 patients who underwent curative resection of HCC between 1991 and 2000 at five university hospitals. Seventy-four patients with 10 years of recurrence-free survival were identified and followed up. They were divided into two groups, 60 recurrence-free and 14 with recurrence after a 10-year recurrence-free period.
Results: Overall survival rates of recurrence and non-recurrence groups were 68 and 91 % at 16 years, and 34 and 91 % at 20 years (p = 0.02), respectively. There were five (36 %), and two deaths (3 %), respectively, after 10 recurrence-free years. A second resection for recurrence was performed in four patients (29 %), and mean survival was 15.3 years after the first hepatectomy. Although three patients in the non-recurrence group (5 %) developed esophageal and/or gastric varices, seven patients in the recurrence group (50 %) developed varices during 10 years (p < 0.0001). In multivariate analysis, preoperative and 10-year platelet count was identified as a favorable independent factor for maintained recurrence-free survival after a 10-year recurrence-free period following curative hepatic resection of HCC.
Conclusions: Recurrence of HCC may occur even after a 10-year recurrence-free period. Long-term follow-up after resection of HCC is important, and should be life-long. Patients with higher preoperative and 10-year platelet counts are more likely to have long-term survival after resection. A low platelet count, related to the degree of liver fibrosis, is a risk factor for recurrence and survival of HCC after curative resection.
Yan H, Zhou D, Liu X, Wang P, Jiang T, Yang Z Front Pharmacol. 2025; 15():1449603.
PMID: 39834808 PMC: 11744000. DOI: 10.3389/fphar.2024.1449603.
Zhang Y, Wang R, Yang X Medicine (Baltimore). 2018; 97(51):e13696.
PMID: 30572498 PMC: 6320186. DOI: 10.1097/MD.0000000000013696.
Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G Liver Cancer. 2018; 7(3):261-276.
PMID: 30319984 PMC: 6170901. DOI: 10.1159/000486902.
Ho S, Liu P, Hsu C, Hsia C, Su C, He Y Sci Rep. 2018; 8(1):15074.
PMID: 30305679 PMC: 6180073. DOI: 10.1038/s41598-018-33536-2.
Differences in the impact of prognostic factors for hepatocellular carcinoma over time.
Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y Cancer Sci. 2017; 108(12):2438-2444.
PMID: 28945309 PMC: 5715354. DOI: 10.1111/cas.13406.